top of page
야외 모임

Communication

Exostemtech applied for phase 1 clinical trial IND in Korea for an exosome-based osteoarthritis trea

Updated: Sep 28, 2022




"EST-P-EXO1" aims to regenerate damaged cartilage tissue and suppress pain


Bio-venture Exostemtech has applied for the domestic clinical trial plan (IND) for the first time in Korea.


Exostemtech, a company specializing in developing exosome-based treatments, announced on the 21st that it has applied for a clinical trial plan (IND) to the Ministry of Food and Drug Safety to proceed with phase 1 clinical trials in Korea for osteoarthritis treatment candidate "EST-P-EXO1" (CARTISOME®).


In this phase 1, Exostemtech evaluates the safety of EST-P-EXO1 in patients with knee osteoarthritis. This clinical trial will be conducted at the Catholic University of Korea Uijeongbu St. Mary's Hospital for up to 28 patients.



Commentaires


bottom of page